Reports of COVID-19 vaccine side effects keep showing up in the news regularly. The one vaccine that received much negative publicity is Oxford-AstraZeneca’s vaccine, which is sold as Covishield in India. This is one of the two vaccines that were approved for use in the country when the mass vaccination drive kicked off. The other vaccine is India’s indigenous vaccine, Covaxin, manufactured by Bharat Biotech. In India too, there have been reports of people experiencing adverse reactions after getting the Covishield jab. But these are mostly minor, and, except a few cases, the going was smooth. According to a report submitted by the National AEFI (Adverse Event Following Immunization) Committee to the Ministry of Health and Family Welfare (MoHFW), there have been 26 cases of severe side effects where recipients suffered from blood clots. The National AEFI looked into complaints after some countries raised alerts on post-vaccination “embolic and thrombotic events” on March 11 this year, particularly with the AstraZeneca-Oxford vaccine. These alerts led to the decision to conduct an urgent in-depth analysis of the adverse events (AE) in India in the light of the global concerns.
Sent from my LLD-AL10 using Tapatalk
